🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Katherine L. Pogue–Geile

NSABP Foundation

ORCID: 0000-0002-9855-046X
MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 7 papers. Top paper: “Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group”.

Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group

npj Breast Cancer(2020)10.1038/s41523-020-0154-2
N/A
3.5DataRank · unranked
168 citations

Elisabeth Specht Stovgaard, Eva Balslev, Jeppe Thagaard, Weijie Chen, Sarah Dudgeon +95 more

Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer

npj Breast Cancer(2020)10.1038/s41523-020-0156-0
N/A
0.801DataRank · unranked
208 citations

Elvire Roblin, Rim S. Kim, Stefan Michiels, Brandon D. Gallas, Weijie Chen +95 more

Clinical Treatment Score Post-5 Years (CTS5) and Late Recurrence Risk in Hormone Receptor–Positive, HER2-Positive Breast Cancer

Journal of the National Comprehensive Cancer Network(2024)10.6004/jnccn.2024.7015
N/A
0.104DataRank · unranked
1 citations

Tanmayi Pai, Yaohua Ma, Zhuo Li, Angelica Gil, Alvaro Moreno‐Aspitia +7 more

Immune landscape in invasive ductal and lobular breast cancer reveals a divergent macrophage-driven microenvironment

Nature Cancer(2023)10.1038/s43018-023-00527-w
N/A
0DataRank · unranked
76 citations

Jian Cui, Jian Zou, Carly Cardello, Anthony R. Cillo, Mostofa Rafid Uddin +12 more

Testing of a machine learning (ML) model for ability to predict oxaliplatin and bevacizumab (bev) benefit in NRG Oncology/NSABP C-07 and C-08.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.3607
N/A
0DataRank · unranked
1 citations

Lujia Chen, Ying Wang, Chunhui Cai, Rim S. Kim, Corey Lipchik +12 more

Examination of the tumor immune microenvironment (TIME) with multispectral immunofluorescence (m-IF): Association of markers with prognosis and bevacizumab (bev) benefit in NRG Oncology/NSABP C-08.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.3516
N/A
0DataRank · unranked
0 citations

Marion Joy, Ying Wang, Nan Song, Rim S. Kim, Greg Yothers +12 more

Association of multiplex-immunofluorescence (m-IF) and gene expression signature with prognosis and bevacizumab (bev) treatment outcomes in NRG oncology/NSABP C-08: Implications for combining immune checkpoint blockade (ICB) and bev.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.4_suppl.140
N/A
0DataRank · unranked
0 citations

Marion Joy, Ying Wang, Rim S. Kim, Patrick G. Gavin, Debora Fumagalli +13 more